Form 6-K — CureVac N.V.: departure of the Company's Chief Technology Officer (January 17, 2022)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of January, 2022, Commission File Number 001-39446. It states that on January 17, 2022 the company issued a press release announcing the departure of its Chief Technology Officer, effective as of January 31, 2022. The information is incorporated by reference into Form F-3, File No. 333-259613, except for statements of the Chairman of the Supervisory Board, the Chief Executive Officer and the Chief Technology Officer in the exhibit. The press release is listed as Exhibit 99.1.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: departure of the Company's Chief Technology Officer (January 17, 2022).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2022-01-18-0001104659-22-004678-234ee5d7ce/
, SHA-256 937f6c03d38458a7c86ae9e2bcfabdf59470bd79667542b51da5162c04c971f2.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2022 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On January 17, 2022, CureVac N.V. (the “Company”) issued a press release announcing the departure of the Company’s Chief Technology Officer, effective as of January 31, 2022. The information included in this Form 6-K (including Exhibit 99.1, but excluding the statements of CureVac N.V.’s Chairman of the Supervisory Board, Chief Executive Officer and Chief Technology Officer contained in Exhibits 99.1 thereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: January 17, 2022 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated January 17, 2022.
File and source
- File
- SEC_CVAC_6-K_filed2022-01-18_0001104659-22-004678.htm
- Size
- 14,263 bytes
- SHA-256
- 937f6c03d38458a7c86ae9e2bcfabdf59470bd79667542b51da5162c04c971f2
- Original
- www.sec.gov